Abstract Background The Oncotype DX breast recurrence score has been introduced more than a decade ago to aid physicians in determining the need for systemic adjuvant chemotherapy in patients with early-stage, estrogen receptor (ER)+, lymph node-negative breast cancer. Methods In this study, we utilized data from The Surveillance, Epidemiology, and End Results (SEER) Program to investigate temporal trends in Oncotype DX usage among US breast cancer patients in the first decade after the introduction of the Oncotype DX assay. Results We found that the use of Oncotype DX has steadily increased in the first decade of use and that this increase is associated with a decreased usage of chemotherapy. Patients who utilized the Oncotype DX test tend...
Purpose: Oncotype Dx 21-gene assay recurrence score (RS) pre-dicts recurrence of early-stage breast ...
WOS: 000453611000008PubMed ID: 27081583Introduction: Breast cancer is the most common malignancy amo...
International audienceBACKGROUND:The 21-gene Oncotype DX Recurrence Score assay is a validated assay...
Background: The Oncotype DX breast recurrence score has been introduced more than a decade ago to ai...
AbstractIntroductionThe use of chemotherapy in node-negative, (O)Estrogen Receptor (ER)-positive bre...
Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is u...
The Oncotype DX® assay was developed to address the need for optimizing the selection of adjuvant sy...
Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-positive, human e...
The decision for adjuvant therapy in women with early stage breast cancer (ESBC) has historically be...
Zhen Rong Siow,1–3 Richard H De Boer,2,3 Geoffrey J Lindeman,1–4 G Bruce Mann2–4 ...
Objective: To explore the long-term outcome of patients who underwent Oncotype DX® testing. The rela...
Background: Oncotype DX testing has reduced the use of adjuvant chemotherapy in node-negative early ...
Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuva...
Purpose: Oncotype Dx 21-gene assay recurrence score (RS) pre-dicts recurrence of early-stage breast ...
WOS: 000453611000008PubMed ID: 27081583Introduction: Breast cancer is the most common malignancy amo...
International audienceBACKGROUND:The 21-gene Oncotype DX Recurrence Score assay is a validated assay...
Background: The Oncotype DX breast recurrence score has been introduced more than a decade ago to ai...
AbstractIntroductionThe use of chemotherapy in node-negative, (O)Estrogen Receptor (ER)-positive bre...
Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is u...
The Oncotype DX® assay was developed to address the need for optimizing the selection of adjuvant sy...
Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-positive, human e...
The decision for adjuvant therapy in women with early stage breast cancer (ESBC) has historically be...
Zhen Rong Siow,1–3 Richard H De Boer,2,3 Geoffrey J Lindeman,1–4 G Bruce Mann2–4 ...
Objective: To explore the long-term outcome of patients who underwent Oncotype DX® testing. The rela...
Background: Oncotype DX testing has reduced the use of adjuvant chemotherapy in node-negative early ...
Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuva...
Purpose: Oncotype Dx 21-gene assay recurrence score (RS) pre-dicts recurrence of early-stage breast ...
WOS: 000453611000008PubMed ID: 27081583Introduction: Breast cancer is the most common malignancy amo...
International audienceBACKGROUND:The 21-gene Oncotype DX Recurrence Score assay is a validated assay...